Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 5/20 | 0.39 |
| ▸ | FPR2 | P25090 | 4/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MC1R | Q01726 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17799747 | 0.86 | TAS1R3 (0.39) | HPGDTAS1R3TAS1R1TAS1R2FPR1 | |
| SCHEMBL17799701 | 0.86 | TAS1R3 (0.39) | HPGDTAS1R3TAS1R1TAS1R2FPR1 | |
| SCHEMBL17799753 | 0.84 | F10 (0.39) | HPGDFPR1FPR2HCRTR1MC1R | |
| SCHEMBL17799733 | 0.81 | HCRTR1 (0.50) | HPGDTAS1R3TAS1R1TAS1R2HCRTR1 | |
| SCHEMBL17799737 | 0.81 | RAB9A (0.46) | TAS1R3TAS1R1TAS1R2HCRTR2RAB9A | |
| SCHEMBL17799696 | 0.81 | ALDH1A1 (0.38) | TAS1R3TAS1R1TAS1R2FPR1FPR2 | |
| SCHEMBL17799691 | 0.80 | TSHR (0.56) | HPGDL3MBTL1RAB9A | |
| SCHEMBL17799692 | 0.80 | HCRTR1 (0.49) | TAS1R3TAS1R1TAS1R2HCRTR1HCRTR2 | |
| SCHEMBL17799632 | 0.78 | EGFR (0.46) | HPGDTAS1R3TAS1R1TAS1R2FPR1 | |
| SCHEMBL31622401 | 0.78 | HPGD (0.43) | HPGDTAS1R3TAS1R1TAS1R2FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50724-E1 | 4-membered ring carboxamides used as nematicides | SYNGENTA CROP PROTECTION AG (CH) | 2026-01-06 | — | — | US | disclosed |
| EP-3019476-B1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-17 | — | — | EP | disclosed |
| US-9867371-B2 | 4-membered ring carboxamides used as nematicides | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | TUBA3C, DDT, CYCS | HPGD 1934/4885TAS1R3 3195/4885TAS1R1 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.